IMPAACT 2022 - Phase II Study of the Virologic Efficacy and Feasibility of Long Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV

Study Status Study Restriction

In Development

United States

What is IMPAACT 2022?

IMPAACT 2022 is a Phase II, multi-center, open-label, non-comparative study to evaluate the effectiveness, feasibility, and pharmacokinetics of long-acting injectable cabotegravir and rilpivirine in non-adherent HIV-1 infected youth. This study will assess the rate of virologic control of these long acting antiretroviral medications among 70 non-adherent youth age 13 to <25 years.

Sites where the study is implemented:

CRS ID Site Name City Country
Site Selection in progress.

Study contacts:

Study Co-Chair: Allison Agwu

Study Co-Chair: Ethel Weld

DAIDS Medical Officer: Adeola Adeyeye

NICHD Medical Officer: Bill Kapogiannis

Clinical Trials Specialist: Emily Brown

Clinical Trials Specialist: Sarah Buisson

Clinical Trials Specialist: Kathleen George

Consultant: Liza Dawson

Data Manager: Yvonne Woolwine-Cunningham

Data Manager: Bonnie Zimmer

Investigator: Thuy Anderson

Laboratory Data Manager (LDM): Rebecca LeBlanc

Laboratory Specialist: Nicole Tobin

Laboratory Technologist: Natasha Samsunder

Protocol Pharmacist: Shawn Chiambah

Protocol Pharmacist: Irene Rwakazina

Statistician: Meredith Warshaw


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.